All In Biotech

Drug Trial Radar · NCT00162461

Evaluation of CYP2C9 Activity

The Use of Phenytoin Metabolic Ratio as a Putative Marker of CYP2C9 Activity In-vivo

Last checked: Nov 19, 2026Latest source record: Jun 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,200

Planned (sponsor's estimate)

Start

Aug 1998

Primary completion

Dec 2020

Study completion Dec 2020

Sponsor

Lead sponsor
Hadassah Medical OrganizationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States - Israel Binational Science Foundation
First posted
Sep 13, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 20 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9. The purpose of the present study is: 1. To confirm the use of phenytoin metabolic ratio as a marker of CYP2C9 activity 2. To correlate phenytoin metabolic ratio with CYP2C9 genotype 3. To study the frequency distribution of CYP2C9 activity in-vivo

Conditions

  • Healthy

Interventions

  • Phenytoin single dose (300 mg)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Correlation between phenytoin metabolic ratio and CYP2C9 genotypeTime frame: 24 hours
  2. Frequency distribution of phenytoin metabolic ratio in the populationTime frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah Medical Organization

    Jerusalem, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.